Ovuplant 2.1mg

Main information

  • Trade name:
  • Ovuplant 2.1mg
  • Pharmaceutical form:
  • Implant
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Ovuplant 2.1mg
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • releasing hormones
  • Therapeutic area:
  • Horses

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0259/001
  • Authorization date:
  • 17-02-2010
  • EU code:
  • UK/V/0259/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised17/06/2010 –AN00299/2009

1. NAMEOFVETERINARYMEDICINALPRODUCT

Ovuplant ®

2.1mgImplantationTabletsforHorses(Mares)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachimplantationtabletsupplies2.1mgDeslorelin(asDeslorelinAcetate).

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Implantationtablets.

Solidcylindricalimplantforsubcutaneoususe.Theimplantisapproximately2.3mmindiameterand

3.6mminlengthandissuppliedinapreloadedplasticsyringewithanattachedstainlesssteelneedle.

4. CLINICALPARTICULARS

4.1 Targetspecies

Horses(non-pregnantmares)

4.2 Indicationsforuse,specifyingthetargetspecies

Inmares:zootechnicaltreatmentfortheinductionofovulationwithin48hours,duringoestrusin

normallycyclingmares(insexualseason),withanovarianfolliclegreaterthan30mmdiameter.

4.3 Contraindications

Cf.Section4.7

4.4 Specialwarningsforeachtargetspecies

Maresshouldbeimplantedwiththeveterinarymedicinalproductwhenadevelopingovarianfollicle

greaterthan30mmindiameterhasbeendetectedbyrectalpalpationand/orultrasonography.In

largerbreeds,itmaybenecessarytowaituntilthedominantfolliclehasprogressedto35mmin

diameterbeforeadministrationoftheveterinarymedicinalproduct.

Treatedmaresshouldbebredorinseminatedwithinthenext48hours.Themareshouldbemonitored

toensurethatovulationhasoccurredandthatfurtherbreedingsarenotrequired.Ifovulationdoesnot

occurwithin48hoursofimplantation,continuebreedingaccordingtoroutinemanagement

procedures.

Ithasbeennotedthatfolliclesweresignificantlysmallerbeforeovulationfordeslorelintreatedmares

comparedwithplacebomares.However,treatmenthadnoeffectonthepercentageofmares

pregnantatdays18or50.

Foralltrialsthatevaluatedconceptionandpregnancyrate,therewerenodifferencesbetween

deslorelin-treatedandnon-treatedmaresattheendofthestudy.

Efficacyhasnotbeenestablishedformaresinvernal(spring)transitionphase.

Revised17/06/2010 –AN00299/2009

4.5 Specialprecautionsforuse

(i) Specialprecautionsforuseinanimals

Donotuseifthefoilpouchisbroken.

Onlyoneimplantshouldbeimplantedpermareduringagivenoestrus.

Theveterinarymedicinalproducthasnotbeentestedinmareslessthanthree(3)yearsofage.

Useonlyinmaresfitforreproduction.

(ii) Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

PregnantwomenshouldnotadministertheveterinarymedicinalproductasGnRHanalogueshave

beenshowntobefoetotoxicinlaboratoryanimals.

Whenadministeringtheveterinarymedicinalproduct,takecaretoavoidaccidentalself-injectionby

ensuringthatanimalsaresuitablyrestrainedandtheapplicationneedleisshieldeduntilthemomentof

implantation.

Inthecaseofaccidentalself-injection,seekmedicalassistanceimmediately,withaviewtohaving

theimplantremoved,asGnRHanaloguesmayhaveadverseeffectsonthemaleandfemale

reproductivesystems.

Althoughskincontactwiththeveterinarymedicinalproductisunlikely,shouldthisoccur,washthe

exposedareaimmediatelywithsoapandwater,asGnRHanaloguesmaybeabsorbedthroughthe

skin.

4.6 Adversereactions(frequencyandseriousness)

Localisedswellingandmildfibrosisatthesiteofimplantationhasbeenobservedinsomemares,

accompaniedbyaslightincreaseinsensitivitytotouchandanelevatedskintemperature.These

effectsaretransientandusuallyresolvewithouttreatmentwithin2to5days.

Somemaresimplantedwiththeveterinarymedicinalproduct(deslorelin)mayexperiencean

increaseddioestrousperiodfollowinguse.

4.7 Useduringpregnancy,lactationorlay

Donotuseduringpregnancy.GnRHanalogueshavebeenshowntobefoetotoxicinlaboratory

animalswhenadministeredduringpregnancy.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

Revised17/06/2010 –AN00299/2009

4.9 Amountstobeadministeredandadministrationroute

Oneimplantshouldbeadministeredbysubcutaneousimplantationinthelateralneckregionmidway

betweentheheadandshoulder.

Preparetheimplantationsitebythoroughlycleaningtheskinwithanappropriatedisinfectant.Insert

theentirelengthoftheneedlesubcutaneouslyandfullydepressthesyringeplunger.Slowlywithdraw

theneedlewhilepressingtheskinattheinsertionsite.Examinethesyringeandneedletoascertain

thattheimplanthasnotremainedwithinthesyringeorneedle.Itmaybepossibletopalpatethe

implantinsitu.

Theimplantisabsorbedanddoesnotrequireremoval.

Donotattempttore-usetheimplanter.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Insafetyandtolerancestudies,theonlysystemicadverseeffectseeninmaresreceivingupto10

implantssimultaneouslywassuppressionofovarianactivity.

4.11 Withdrawalperiods

Meatandoffal:7days.

Donotuseinmaresproducingmilkforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

Group:Gonadotropin-releasinghormones

ATCvetcode:QH01CA93

5.1 Pharmacodynamicproperties

Deslorelinisasyntheticoligopeptideanalogueofgonadotropinreleasinghormoneusedtoadvance

ovulationinoestrusmares.Themechanismofactionofdeslorelincorrespondswiththatofnaturally

occurringGnRH,stimulatingthereleaseoffolliclestimulatinghormoneandluteinisinghormone(LH)

fromthepituitarygland.TheincreasedcirculatingconcentrationofLHpromotesovulationinmares

withadevelopingfolliclegreaterthan30mmindiameter.Theuseofanimplantformulationwhich

releasesdeslorelinoverashorttimeperiodresultsinapre-ovulatorypeakofLHwithinanarrow

timeframe,therebyinducingovulationwithin48hoursinahighproportionofmares.The

advancementofovulationinthiswaydecreasesthedurationofoestrusandallowscloser

synchronisationofmatingwithovulation.

5.2 Pharmacokineticparticulars

Nodirectmeasurementofdeslorelinreleaseinvivohasbeencarriedoutinthetargetspecies.Due

tothemodeofactionandrapidmetabolismofdeslorelin,directmeasurementofthesubstancein

plasmaisnotpracticable.Toovercomethis,indirectmarkersofdeslorelinhavebeenusedby

assayingbloodconcentrationsofLHandFSH.TheobservationofincreasedLHandFSH

concentrationsinbloodat12–48hoursafterimplantationprovidesindirectevidencethatreleaseof

deslorelinisoccurring.

Revised17/06/2010 –AN00299/2009

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Calciumhydrogenphosphatedihydrate

Hydrogenatedvegetableoil

6.2 Incompatibilities

Noneknown.

6.3 Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:2years.

6.4 Specialprecautionsforstorage

Storeinarefrigerator(2°C-8°C).

6.5 Natureandcontentsofimmediatepackaging

Theimplantissuppliedpreloadedinapolypropylenesyringewithanattachedstainlesssteel

needle.Eachpreloadedimplanterissuppliedinasealedfoilpouch.5ofthesearepackagedina

cardboardcarton.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts,ifappropriate

Anyunusedproductorwastematerialsshouldbedisposedofinaccordancewithnational

requirements.

7. MARKETINGAUTHORISATIONHOLDER

DechraLimited

DechraHouse

JamageIndustrialEstate

TalkePits

Stoke-on-Trent

Staffordshire

ST71XW

UnitedKingdom

8. MARKETINGAUTHORISATIONNUMBER

UK:Vm10434/4063

IE:VPA10799/017/001

9. DATEOFRENEWALOFTHEAUTHORISATION

14January2010

10. DATEOFANYREVISIONOFTHETEXT

Revised17/06/2010 –AN00299/2009

17June2010

30-10-2018

FDA takes action to stop the use of lead acetate in hair dyes

FDA takes action to stop the use of lead acetate in hair dyes

FDA takes action to stop the use of lead acetate in hair dyes. FDA will no longer allow lead acetate to be used in certain hair coloring products based on data that demonstrate that there is no longer a reasonable certainty of no harm from the use of this color additive.

FDA - U.S. Food and Drug Administration

10-8-2018

FDA approves new vaginal ring for one year of birth control

FDA approves new vaginal ring for one year of birth control

FDA approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration

15-3-2018

Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

OTTAWA - Health Canada is advising Canadians that it will be conducting a safety review of Fibristal (ulipristal acetate), a medication used to treat uterine fibroids in women. Health Canada's review is a result of Canadian and European reports of serious adverse events affecting the liver.

Health Canada

21-11-2018

Osurnia (Elanco GmbH)

Osurnia (Elanco GmbH)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7842 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/003753/T/0010

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2086 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/18/2086 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/18/2086 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate) - Orphan designation - Commission Decision (2018)7795 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/106/18

Europe -DG Health and Food Safety

1-10-2018

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Active substance: Icatibant acetate) - Transfer of orphan designation - Commission Decision (2018)6432 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/054/02/T/01

Europe -DG Health and Food Safety

29-8-2018

Ulipristal Acetate Gedeon Richter (Gedeon Richter Plc.)

Ulipristal Acetate Gedeon Richter (Gedeon Richter Plc.)

Ulipristal Acetate Gedeon Richter (Active substance: Ulipristal Acetate) - Centralised - Authorisation - Commission Decision (2018)5779 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/5017

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2058 (IQVIA RDS Ireland Limited)

EU/3/18/2058 (IQVIA RDS Ireland Limited)

EU/3/18/2058 (Active substance: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate) - Orphan designation - Commission Decision (2018)5730 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/099/18

Europe -DG Health and Food Safety

6-8-2018

Cetrotide (Merck Europe B.V.)

Cetrotide (Merck Europe B.V.)

Cetrotide (Active substance: Cetrorelix (as acetate)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5373 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/233/T/67

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt) - Transfer of orphan designation - Commission Decision (2018)3797 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/16/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt) - Transfer of orphan designation - Commission Decision (2018)3798 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/166/12/T/01

Europe -DG Health and Food Safety

29-5-2018

Osurnia (Elanco Europe Ltd)

Osurnia (Elanco Europe Ltd)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Yearly update - Commission Decision (2018)3406 of Tue, 29 May 2018

Europe -DG Health and Food Safety

17-4-2018

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Active substance: Ornithine phenylacetate) - Transfer of orphan designation - Commission Decision (2018)2355 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/105/11/T/03

Europe -DG Health and Food Safety